{"id":3890,"date":"2015-06-04T16:01:01","date_gmt":"2015-06-04T16:01:01","guid":{"rendered":"http:\/\/hivcareconnect.com\/?p=3890"},"modified":"2022-01-06T16:31:02","modified_gmt":"2022-01-06T16:31:02","slug":"for-providers-and-pharmacies-cdph-alert-invasive-meningococcal-disease-in-men-who-have-sex-with-men","status":"publish","type":"post","link":"https:\/\/hivcareconnect.com\/for-providers-and-pharmacies-cdph-alert-invasive-meningococcal-disease-in-men-who-have-sex-with-men\/","title":{"rendered":"For providers and pharmacies: CDPH alert: Invasive meningococcal disease in men who have sex with men"},"content":{"rendered":"
Date: June 3, 2015<\/span><\/p>\n To: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 HIV primary care providers, pharmacies co-located with HIV clinics, Centers of Excellence pharmacies<\/span><\/p>\n From: \u00a0\u00a0\u00a0\u00a0 Stephanie Black, MD, MSc, Medical Director, Communicable Diseases Program and\u00a0Sarah Kemble, MD, Medical Director, Communicable Diseases Program<\/span><\/p>\n CDPH Alert: Invasive Meningococcal Disease in Men Who Have Sex with Men<\/strong><\/span><\/p>\n Since mid-May 2015, the Chicago Department of Public Health (CDPH) has been actively investigating reports of 3 confirmed cases of invasive meningococcal disease (IMD) in men who have sex with men (MSM), one of which was fatal. All 3 N. meningitidis <\/em>isolates are serogroup C. Characteristics of cases include HIV diagnosis or use of on-line \u201chook-up\u201d apps to seek sexual partners (e.g., Grindr, Jack\u2019d, Adam4Adam).<\/span><\/p>\n Among HIV-positive MSM in Chicago, the annual incidence rate of IMD in 2015 has reached about 23\/100,000, surpassing the Advisory Committee on Immunization Practices (ACIP) recommended threshold of 10\/100,000 for initiating a meningococcal vaccination campaign.1<\/span><\/p>\n Due to this cluster, CDPH is recommending meningococcal vaccination for<\/strong>\u00a01) HIV-positive MSM and<\/strong>\u00a02) MSM regardless of HIV status who have close or intimate contact with anonymous partners or<\/strong>\u00a0seek sexual partners through the use of on-line \u201chook-up\u201d apps.<\/strong><\/span><\/p>\n In 2003, an outbreak of IMD occurred among MSM in Chicago.2 From 2010-2013, an outbreak of IMD in MSMwas identified in New York City; cases included HIV-positive MSM and MSM who used digital applications tomeet sexual partners.3<\/span><\/p>\n Obtaining meningococcal vaccine: <\/strong>Men in the risk categories defined above may obtain vaccine throughone of 3 methods:<\/span><\/p>\n The CDPH Immunization Program will provide meningococcal vaccine for patients that meet the CDPH vaccination recommendation, regardless of insurance status. If you wish to order vaccine, contact Kevin Hansen at 312-746-9330 or via email at kevin.hansen@cityofchicago.org<\/a>.<\/span><\/p>\n In addition, a provider hotline at 312-746-4835 is available from 8:30a-4:30p.Two meningococcal conjugate vaccines (i.e., Menactra, Menveo) that contain serogroups A, C, W135, and Yare licensed for use in adults through age 55 years. Non-immunocompromised adults only need one dose for adequate protection; HIV-infected and other immunocompromised individuals should receive 2 doses, 8 weeks apart (i.e., at 0 and 2 months). Meningococcal polysaccharide vaccine (i.e., Menomune) should be used for adults aged 56 and older.<\/span><\/p>\n Clinical manifestations: <\/strong>Patients with meningococcal disease characteristically present with fever, headache, stiff neck, petechial rash, sepsis, and\/or altered mental status. Early in the course, an abnormality in pulse,blood pressure or respiratory rate out of proportion to the physical examination may be the only indication of a serious infection. Rapid recognition of IMD with administration of appropriate antibiotics increases the probability of survival. Treatment with antibiotics should not be delayed pending the results of diagnostic testing. Early clues to meningococcal disease may include:<\/span><\/p>\n Timely antibiotic prophylaxis reduces the risk of transmission to close contacts, but must be administered as soon as possible and within 10 days of the last exposure. CDPH routinely investigates all IMD cases to identify close contacts and assists providers with administering antibiotic prophylaxis. Persons that should receive prophylaxis include:<\/span><\/p>\n Additional information from the Centers for Disease Control and Prevention about N. meningitidis <\/em>infection and meningococcal vaccines can be found at: http:\/\/www.cdc.gov\/meningococcal\/index.html<\/a> and\u00a0http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6003a3.htm<\/a><\/span><\/p>\n Please remember to report cases of IMD to CDPH immediately. <\/strong>Please also ensure that bacterial isolates are submitted to the Illinois Public Health Laboratory for serogrouping and molecular typing in a timely fashion. To report a suspect or confirmed case of meningococcal disease please call:Business hours: 312-746-5377 or 312-746-5925; Non-business hours: Call 311 and ask for the communicable disease physician on-call.<\/span><\/p>\n References<\/strong><\/span><\/p>\n Date: June 3, 2015 To: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 HIV primary care providers, pharmacies co-located with HIV clinics, Centers of Excellence pharmacies From: \u00a0\u00a0\u00a0\u00a0 Stephanie Black, MD, MSc, Medical Director, Communicable Diseases Program and\u00a0Sarah Kemble, MD, Medical Director, Communicable Diseases Program CDPH Alert: Invasive Meningococcal Disease in Men Who Have Sex with Men Since mid-May 2015, the ChicagoRead More<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-3890","post","type-post","status-publish","format-standard","hentry","category-news","has-post-title","no-post-date","has-post-category","has-post-tag","has-post-comment","has-post-author",""],"_links":{"self":[{"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/posts\/3890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/comments?post=3890"}],"version-history":[{"count":8,"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/posts\/3890\/revisions"}],"predecessor-version":[{"id":10217,"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/posts\/3890\/revisions\/10217"}],"wp:attachment":[{"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/media?parent=3890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/categories?post=3890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hivcareconnect.com\/wp-json\/wp\/v2\/tags?post=3890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
\n
\n
\n
\n